MPA Case Study
The Need: Lead Selection for a Virus-Neutralizing Antibody
In response to the COVID-19 pandemic, Abound Bio developed potent neutralizing monoclonal antibodies (MAbs) against SARS-CoV-2. To progress development of a lead MAb, the company sought reassurance that their preclinical candidate did not possess off-target reactivity to human membrane proteins that could result in toxic effects. Off-target reactivity of therapeutic MAbs has been observed with other SARS-CoV-2 MAbs, so testing across the membrane proteome helps to validate therapeutic safety.
.png)
The Solution: The Membrane Proteome Array to Rule Out Off-Target Liabilities
Integral Molecular’s Membrane Proteome Array™ (MPA) was used to profile a high-affinity antibody that potently neutralizes SARS-CoV-2 by blocking its binding to the ACE2 protein, the receptor interaction driving infection. Abound Bio is developing this antibody for the treatment of COVID-19.
"For this high-priority project, we relied on Integral Molecular’s rapid specificity profiling to rule out liabilities arising from unexpected antibody cross-reactivity in human cells."
-Dimiter Dimitrov, PhD, ScD
CSO, Abound Bio
The Impact: MAb Progression for Development
Data featured in Li et al., 2020
.png)
"MPA technology quickly provided us with the reassurance that Abound Bio’s potent, neutralizing antibodies to SARS-CoV-2 did not bind off-target human membrane proteins which could be associated with toxicity."
-John W. Mellors, MD
CEO, Abound Bio